GPX4 and cancer: Novel nitroisoxazole‐containing spiro[pyrrolidine‐oxindoles] (39) were designed as dual inhibitors of GPX4 and mouse double minute 2 (MDM2) (Figure 3) to induce both ferroptosis and apoptosis in cancer cells.